• Cardiovascular: David Caouette — david_caouette@merckandcoinc.net
• Diabetes: Lee Davies — lee.davies@merckandcoinc.net
• Oncology: Pamela Eisele — pamela_eisele@merckandcoinc.net
• Bone, Respiratory, Immunology & Dermatology: Ian McConnell — ian_mcconnell@merckandcoinc.net
• Neurosciences & Ophthalmology: Monique Mols — monique.mols@merckandcoinc.net

Browse past announcements by category:

• Prescription Medicine News
• Consumer Care News
• Vaccine News
• Research & Development News
• Corporate News
• Financial News
• Corporate Responsibility News
• Schering-Plough News Archive

The newsroom serves as the central hub for all corporate communications, providing timely updates on the company's activities across prescription medicine, consumer healthcare, vaccines, and ongoing research initiatives. Journalists and analysts rely on this resource for verified statements and official announcements. The content here reflects the organization's commitment to transparency and accurate reporting, with materials prepared by the communications team for distribution to media outlets worldwide. Regular updates ensure that stakeholders have access to the latest developments in clinical programs, regulatory milestones, and corporate governance matters.

Media inquiries are handled through a dedicated team that coordinates responses across multiple therapeutic areas. The communications staff works closely with subject matter experts to provide accurate information on complex topics ranging from cardiovascular treatments to oncology research. Each inquiry receives careful attention, with the goal of delivering clear, factual responses that support informed reporting. The media relations function operates within strict guidelines to ensure consistency and compliance with industry regulations, maintaining the trust of journalists and the broader public.

Corporate statements issued through the newsroom cover a wide range of topics including research breakthroughs, policy positions, and community engagement efforts. These statements are crafted to provide context and clarity on matters that affect patients, healthcare providers, and investors. The company recognizes the importance of clear communication in an era of rapid information exchange, and the newsroom plays a vital role in ensuring that official positions are accurately represented. Archived materials are available for reference, offering a complete record of past announcements.

The company's research pipeline spans multiple disease areas, with ongoing studies exploring new approaches to treatment and prevention. Newsroom content highlights significant milestones in drug development, from early-stage trials to regulatory submissions. The organization maintains a strong focus on areas of unmet medical need, investing in science that has the potential to improve patient outcomes. Updates on clinical progress are shared regularly, providing the media and public with insight into the company's long-term commitment to innovation and scientific excellence.

Beyond product announcements, the newsroom features information about corporate responsibility initiatives, partnerships with academic institutions, and efforts to expand access to healthcare. These stories demonstrate the broader impact of the organization beyond its commercial activities. The company's approach to stakeholder communication emphasizes honesty and accountability, with the newsroom serving as a trusted source for information on both successes and challenges. This commitment to open dialogue helps build lasting relationships with the communities served around the world.